Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040).
Saved in:
| Title: | Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040). |
|---|---|
| Authors: | Sangro B; Liver Unit, Clinica Universidad de Navarra-IDISNA and CIBEREHD, Pamplona, Spain., Yau T; University of Hong Kong, Hong Kong Special Administrative Region, Pokfulam, China., El-Khoueiry AB; Keck School of Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, California, USA., Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan., Shen Y; Bristol Myers Squibb, Princeton, New Jersey, USA., Tschaika M; Bristol Myers Squibb, Princeton, New Jersey, USA., Roy A; Bristol Myers Squibb, Princeton, New Jersey, USA., Feng Y; Bristol Myers Squibb, Princeton, New Jersey, USA., Gao L; Bristol Myers Squibb, Princeton, New Jersey, USA., Aras U; Bristol Myers Squibb, Princeton, New Jersey, USA. |
| Source: | Clinical and translational science [Clin Transl Sci] 2023 Aug; Vol. 16 (8), pp. 1445-1457. Date of Electronic Publication: 2023 May 30. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37165980 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Sangro+B%22">Sangro B</searchLink>; Liver Unit, Clinica Universidad de Navarra-IDISNA and CIBEREHD, Pamplona, Spain.<br /><searchLink fieldCode="AU" term="%22Yau+T%22">Yau T</searchLink>; University of Hong Kong, Hong Kong Special Administrative Region, Pokfulam, China.<br /><searchLink fieldCode="AU" term="%22El-Khoueiry+AB%22">El-Khoueiry AB</searchLink>; Keck School of Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Kudo+M%22">Kudo M</searchLink>; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Shen+Y%22">Shen Y</searchLink>; Bristol Myers Squibb, Princeton, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Tschaika+M%22">Tschaika M</searchLink>; Bristol Myers Squibb, Princeton, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Roy+A%22">Roy A</searchLink>; Bristol Myers Squibb, Princeton, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Feng+Y%22">Feng Y</searchLink>; Bristol Myers Squibb, Princeton, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Gao+L%22">Gao L</searchLink>; Bristol Myers Squibb, Princeton, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Aras+U%22">Aras U</searchLink>; Bristol Myers Squibb, Princeton, New Jersey, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101474067%22">Clinical and translational science</searchLink> [Clin Transl Sci] 2023 Aug; Vol. 16 (8), pp. 1445-1457. <i>Date of Electronic Publication: </i>2023 May 30. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22WileyBlackwell+Pub%22">WileyBlackwell Pub </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101474067 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1752-8062 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217528054%22">17528054 </searchLink><i>NLM ISO Abbreviation: </i>Clin Transl Sci <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37165980 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/cts.13544 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1445 Titles: – TitleFull: Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Sangro B – PersonEntity: Name: NameFull: Yau T – PersonEntity: Name: NameFull: El-Khoueiry AB – PersonEntity: Name: NameFull: Kudo M – PersonEntity: Name: NameFull: Shen Y – PersonEntity: Name: NameFull: Tschaika M – PersonEntity: Name: NameFull: Roy A – PersonEntity: Name: NameFull: Feng Y – PersonEntity: Name: NameFull: Gao L – PersonEntity: Name: NameFull: Aras U IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: 2023 Aug Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1752-8062 Numbering: – Type: volume Value: 16 – Type: issue Value: 8 Titles: – TitleFull: Clinical and translational science Type: main |
| ResultId | 1 |